Revvity (NYSE:RVTY) Shares Gap Down to $100.48

Revvity, Inc. (NYSE:RVTY) shares gapped down before the market opened on Thursday . The stock had previously closed at $100.48, but opened at $97.99. Revvity shares last traded at $98.42, with a volume of 95,283 shares changing hands.

Analyst Ratings Changes

Several research firms have recently issued reports on RVTY. Raymond James boosted their target price on Revvity from $106.00 to $127.00 and gave the company an “outperform” rating in a research note on Friday, February 2nd. KeyCorp raised their target price on shares of Revvity from $110.00 to $126.00 and gave the stock an “overweight” rating in a research report on Friday, February 2nd. UBS Group cut shares of Revvity from a “buy” rating to a “neutral” rating and boosted their price target for the company from $105.00 to $125.00 in a research report on Tuesday, January 16th. Stifel Nicolaus lifted their price objective on Revvity from $95.00 to $110.00 and gave the company a “hold” rating in a research report on Friday, February 2nd. Finally, Evercore ISI raised Revvity from an “in-line” rating to an “outperform” rating and increased their target price for the stock from $88.00 to $125.00 in a research report on Thursday, January 4th. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, Revvity has an average rating of “Moderate Buy” and a consensus target price of $118.91.

Revvity Stock Up 1.5 %

The firm has a market capitalization of $12.46 billion, a P/E ratio of 18.34, a P/E/G ratio of 2.62 and a beta of 1.09. The company has a quick ratio of 1.77, a current ratio of 2.07 and a debt-to-equity ratio of 0.40. The company has a fifty day simple moving average of $104.78 and a 200 day simple moving average of $101.64.

Revvity (NYSE:RVTY) last released its quarterly earnings data on Thursday, February 1st. The company reported $1.25 EPS for the quarter, beating the consensus estimate of $1.15 by $0.10. The company had revenue of $695.90 million for the quarter. Revvity had a return on equity of 7.41% and a net margin of 25.20%. On average, equities analysts expect that Revvity, Inc. will post 4.65 EPS for the current fiscal year.

Revvity Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 10th. Investors of record on Friday, April 19th will be given a dividend of $0.07 per share. The ex-dividend date of this dividend is Thursday, April 18th. This represents a $0.28 annualized dividend and a yield of 0.28%. Revvity’s dividend payout ratio (DPR) is 5.09%.

Insider Buying and Selling

In other Revvity news, insider Prahlad R. Singh sold 21,217 shares of the company’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $104.28, for a total value of $2,212,508.76. Following the completion of the sale, the insider now owns 92,801 shares in the company, valued at $9,677,288.28. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 0.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Revvity

A number of hedge funds have recently modified their holdings of the company. Parkside Financial Bank & Trust bought a new position in Revvity in the 4th quarter worth $25,000. Gladius Capital Management LP boosted its stake in shares of Revvity by 84.1% in the third quarter. Gladius Capital Management LP now owns 232 shares of the company’s stock worth $26,000 after acquiring an additional 106 shares during the period. Benjamin F. Edwards & Company Inc. purchased a new stake in shares of Revvity during the fourth quarter worth about $27,000. CENTRAL TRUST Co bought a new stake in Revvity during the 4th quarter valued at approximately $27,000. Finally, ORG Partners LLC purchased a new position in Revvity in the 4th quarter worth approximately $32,000. 86.65% of the stock is currently owned by institutional investors.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.